Ownership and insider activity for Harmony Biosciences Holdings, Inc. (HRMY): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc.
Price
| Price | $37.02 (closing price, November 3, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-16 | Budur Kumar | M-Exempt | 900 | $27K |
| 2026-09-17 | Budur Kumar | M-Exempt | 400 | $12K |
| 2026-09-18 | Budur Kumar | M-Exempt | 25,446 | $770K |
| 2026-09-18 | Budur Kumar | M-Exempt | 25,446 | $770K |
| 2026-09-16 | Budur Kumar | M-Exempt | 900 | $28K |
| 2026-09-17 | Budur Kumar | M-Exempt | 400 | $12K |
| 2026-09-18 | Budur Kumar | M-Exempt | 10,406 | $319K |
| 2026-09-18 | Budur Kumar | M-Exempt | 10,406 | $319K |
| 2026-09-16 | Budur Kumar | M-Exempt | 900 | $27K |
| 2026-09-16 | Budur Kumar | M-Exempt | 900 | $28K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.5M | $24.5M | $228.6M | $234.3M | $243.8M | $311.7M | $453.0M | $752.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | $79.3M | $41.8M | $14.2M | $22.8M |
| Receivables | 0 | $4.3M | $22.2M | $34.8M | $54.7M | $74.1M | $83.0M | $96.8M |
| Inventory | 0 | $1.1M | $3.8M | $4.4M | $4.3M | $5.4M | $7.2M | $5.4M |
| Total Current Assets | $86.7M | $31.5M | $262.9M | $284.4M | $400.3M | $451.1M | $579.3M | $907.0M |
| Property, Plant & Equipment | $1.6M | $1.3M | $938,000 | $4.1M | $573,000 | $371,000 | $3.4M | $5.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $72.2M | $162.3M | $143.9M | $161.0M | $137.1M | $113.3M | $89.4M |
| Total Assets | $89.3M | $106.7M | $427.1M | $433.4M | $673.9M | $811.4M | $999.2M | $1.27B |
| Accounts Payable | $1.5M | $6.4M | $2.6M | $1.0M | $3.8M | $17.7M | $13.7M | $17.7M |
| Short-term Debt | 0 | 0 | 0 | $2.0M | $2.0M | $15.0M | $16.2M | $86.9M |
| Total Current Liabilities | $7.2M | $19.9M | $134.5M | $53.8M | $78.9M | $163.8M | $175.1M | $252.1M |
| Long-term Debt | $324.2M | $97.9M | $194.2M | $190.0M | $189.6M | $178.6M | $163.0M | $148.2M |
| Total Liabilities | $7.8M | $118.3M | $329.9M | $246.9M | $271.0M | $344.5M | $340.0M | $401.4M |
| Retained Earnings | -$242.7M | -$422.9M | -$488.2M | -$453.6M | -$272.1M | -$143.3M | $2.2M | $160.9M |
| Total Equity | $81.5M | -$11.6M | $97.2M | $186.5M | $402.8M | $467.0M | $659.2M | $870.2M |
| Total Debt | $324.2M | $97.9M | $194.2M | $195.7M | $191.6M | $193.6M | $181.4M | $239.6M |
| Net Debt | $240.7M | $73.5M | -$34.4M | -$38.6M | -$131.5M | -$159.9M | -$285.8M | -$535.8M |
| Working Capital | $79.5M | $11.6M | $128.4M | $230.7M | $321.4M | $287.3M | $404.2M | $654.9M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 3.48 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 5.23 |
Profitability
| Return on Equity | 20.06% |
| Return on Invested Capital | 14.96% |
| Return on Assets | 13.20% |
| Gross Margin | 75.42% |
| Operating Margin | 24.03% |
| Net Margin | 18.88% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of HRMY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks